Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

HIV Infection

Free Subscription Articles published in Antivir Ther Retrieve available abstracts of 13 articles: HTML format

Single Articles

August 2026
1. PENNETZDORFER N, Naik V, Montezuma-Rusca JM, Sklar P, et al
   Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study.
   Antivir Ther. 2026;31:13596535261481194.
   PubMed     Abstract available
   
   
   June 2026
2. PANNECOUCKE C, Valin N, Peytavin G, Lambert S, et al
   Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series.
   Antivir Ther. 2026;31:13596535261436877.
   PubMed     Abstract available
   
   
   
3. EFRIDA, Yuza A
   Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review.
   Antivir Ther. 2026;31:13596535261450699.
   PubMed     Abstract available
   
   
   April 2026
4. YOUNG J, Lawler PR, Moodie EEM, Bucher HC, et al
   It's about time: The association between abacavir and cardiovascular disease.
   Antivir Ther. 2026;31:13596535261438178.
   PubMed     Abstract available
   
   
   October 2025
5. DE KOFF EM, van Andel H, de Jong HK, van der Kooi AJ, et al
   Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report.
   Antivir Ther. 2025;30:13596535251385624.
   PubMed     Abstract available
   
   
   June 2025
6. GAO Y, Ji W, Chen Q
   The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis.
   Antivir Ther. 2025;30:13596535251345870.
   PubMed     Abstract available
   
   
   
7. VAN HEMELRYCK S, Van Landuyt E, Deleu S, Leopold L, et al
   Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1.
   Antivir Ther. 2025;30:13596535251349336.
   PubMed     Abstract available
   
   
   April 2025
8. ELEJE GU, Usman HA, Onubogu CU, Fiebai PO, et al
   Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort study.
   Antivir Ther. 2025;30:13596535251333259.
   PubMed     Abstract available
   
   
   
9. PALLANZA M, Thoueille P, Briki M, Alves Saldanha S, et al
   Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.
   Antivir Ther. 2025;30:13596535251335080.
   PubMed     Abstract available
   
   
   
10. LABATE L, Rossetti B, Russo C, Cassol C, et al
    Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database.
    Antivir Ther. 2025;30:13596535251317054.
    PubMed     Abstract available
    
    
    February 2025
11. PICKERING RT, Asundi A, Olson A, Soden K, et al
    Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir.
    Antivir Ther. 2025;30:13596535251314571.
    PubMed     Abstract available
    
    
    December 2024
12. PASSEROTTO RA, Lamanna F, Salvo PF, Iannone V, et al
    Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort.
    Antivir Ther. 2024;29:13596535241306467.
    PubMed     Abstract available
    
    
    April 2024
13. VAN HEMELRYCK S, Van Landuyt E, Hufkens V, Vanveggel S, et al
    Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged >/=6 to <12 years, using matching placebo tablets: A ran
    Antivir Ther. 2024;29:13596535241248282.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum